Mineralocorticoid receptor antagonists in the treatment of patients with chronic heart failure. Positions in 2015
Mineralocorticoid receptor antagonists (MCRA) are part of standard medical therapy for heart failure (HF). The clinical efficacy of MCRA in patients with systolic HF has been proven by randomized clinical trials. The efficacy of this drug group in patients with chronic HF with preserved left ventric...
Main Authors: | Yu F Osmolovskaya, I V Zhirov, S N Tereshchenko |
---|---|
格式: | 文件 |
语言: | Russian |
出版: |
"Consilium Medicum" Publishing house
2015-09-01
|
丛编: | Терапевтический архив |
主题: | |
在线阅读: | https://ter-arkhiv.ru/0040-3660/article/view/31823 |
相似书籍
-
Mineralocorticoid receptor antagonists in the treatment of patients with heart failure after myocardial infarction and those with chronic heart failure
由: S N Tereshchenko, et al.
出版: (2013-12-01) -
Heart failure: the role for mineralocorticoid receptor antagonists
由: Bertram Pitt
出版: (2014-05-01) -
Rational drug therapy of chronic heart failure: the role of mineralocorticoid receptor antagonists: review
由: Natalia V. Safronova, et al.
出版: (2022-01-01) -
Mineralocorticoid receptor antagonists: new extended roles in cardio- and nephroprotection
由: A. M. Esayan, et al.
出版: (2018-04-01) -
Hyperkalaemia as a cause of undertreatment with mineralocorticoid receptor antagonists in heart failure
由: Josefin Henrysson, et al.
出版: (2023-02-01)